Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CureVac N.V. - Ordinary Shares (NQ:CVAC)

4.660 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CureVac N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
Via ACCESS Newswire
News headline image
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
Via ACCESS Newswire
News headline image
Traders are paying attention to the gapping stocks in Friday's session. ↗
Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Top movers in Friday's pre-market session ↗
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators
Via ACCESS Newswire
News headline image
Why CureVac (CVAC) Stock Is Moving ↗
Shares of CureVac fell by 12.3% Wednesday afternoon. The pullback may stem from profit-taking after Tuesday's strong gains driven by rising concerns over U.S. respiratory illnesses. 
Via Benzinga
News headline image
Argan Posts Upbeat Results, Joins KULR Technology, Abacus Global Management, W. R. Berkley And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps ↗
CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in July 2025. 
Via Benzinga
Topics Intellectual Property
News headline image
Wondering what's happening in today's after-hours session? ↗
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
Via ACCESSWIRE
News headline image
Insights into CureVac's Upcoming Earnings ↗
 
Via Benzinga
News headline image
CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
Via ACCESSWIRE
News headline image
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
Via ACCESSWIRE
News headline image
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
Via ACCESS Newswire
News headline image
Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch ↗
A Nevada dairy worker who initially tested positive for bird flu is currently experiencing mild symptoms, including "pink eye." 
Via Benzinga
News headline image
Trump Administration Halts All Communications From The Centers For Disease Control As Bird Flu Spreads ↗
As the bird flu virus continues to spread through the United States, the Trump administration on Tuesday ordered all communications from the Centers for Disease Control and Prevention to stop. 
Via Benzinga
Topics Government
News headline image
Bird Flu Update: First Commercial Case In Georgia, Moderna Receives $590 Million To Develop Vaccine ↗
According to the latest data from the Centers for Disease Control, the current bird flu outbreak has caused 67 human cases of bird flu in the U.S. and one death associated with the virus. 
Via Benzinga
News headline image
Bird Flu Raising Red Flags Among Health Officials, CDC Urges Faster Testing ↗
The CDC issued a health advisory Thursday recommending that hospitalized patients who have tested positive for influenza be tested for the bird flu virus within 24 hours. 
Via Benzinga
News headline image
Why CureVac (CVAC) Shares Are Volatile ↗
CureVac shares have been volatile over the past week, gaining some 25%. The stock has seen increased trading volume following the U.S.'s first human death from H5N1 bird flu. 
Via Benzinga
News headline image
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies ↗
Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind. 
Via Benzinga
Topics ETFs
News headline image
US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally ↗
The Louisiana Department of Health on Monday reported the first human death in the U.S. related to the H5N1 bird flu virus. The CDC is also reporting high levels of acute respiratory illnesses... 
Via Benzinga
News headline image
Why CureVac (CVAC) Stock Is Rising ↗
Shares of CureVac are trading higher by 15% during Monday's session. The stock is gaining following a CDC report highlighting a significant increase in acute respiratory illnesses nationwide. 
Via Benzinga
News headline image
2 Small-Cap Stocks Set to Shine in a Bull Market
Small-cap growth-orientated stocks like HTCR and CVAC often outperform during bullish markets due to their sensitivity to improving economic conditions. 
Via MarketBeat
Topics ETFs
News headline image
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
Via ACCESSWIRE
News headline image
CureVac to Present at the 12th International mRNA Health Conference
Via ACCESSWIRE
News headline image
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Via ACCESSWIRE
News headline image
CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
Via ACCESSWIRE
News headline image
GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza mRNA Vaccine ↗
GSK announced positive phase 2 trial results for its mRNA seasonal flu vaccine, showing strong immune. 
Via Benzinga
News headline image
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.